Tiotropium as Asthma Add-On Treatment Shows Promise
Posted by adminApr 2
Boehringer Ingelheim has announced positive results from several Phase 3 studies analyzing once-daily tiotropium (Spiriva; Boehringer Ingelheim) delivered via the Respimat inhaler as an add-on treatment for patients with varying severities of asthma who remain symptomatic with current therapies. Tiotropium is currently indicated for bronchospasms due to COPD, including chronic bronchitis and emphysema.
Related News
Resus Me Website and referance As described […]
Asbestos flooding B.C. with a ‘steady stream of death’ Interesting article from the […]
The Safe Uses of Lidocaine During Bronchoscopy
Lidocaine is a drug that has a […]
Complications of Inhaled Anticholinergics SOURCE: Journal of the American […]
Warning: Declaration of Social_Walker_Comment::start_lvl(&$output, $depth, $args) should be compatible with Walker_Comment::start_lvl(&$output, $depth = 0, $args = Array) in /home/daugulis/public_html/wp-content/plugins/social/lib/social/walker/comment.php on line 60
Warning: Declaration of Social_Walker_Comment::end_lvl(&$output, $depth, $args) should be compatible with Walker_Comment::end_lvl(&$output, $depth = 0, $args = Array) in /home/daugulis/public_html/wp-content/plugins/social/lib/social/walker/comment.php on line 60
From BCRT.ca Tiotropium as Asthma Add-On Treatment Shows Promise http://t.co/IVhXieAxF9